GSK’s new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog says

Carly Helfand GlaxoSmithKline has a new drug that's tailored for patients with a specific type of severe asthma. But according to a nonprofit body that evaluates drugs' prices ...

GlaxoSmithKline bags an FDA OK for its asthma drug with eyes on a respiratory turnaround

Damian Garde GlaxoSmithKline won FDA approval for an antibody designed to treat severe asthma, leading a pack of drugmakers at work on similar therapies as it seeks to bolster its respiratory ...

ProPublica: Safety questions over GSK’s Advair linger after years on the asthma throne

Carly Helfand U.S. regulators gave GlaxoSmithKline's Advair the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $ 8 billion ...

Regeneron speeds toward the FDA with its would-be asthma blockbuster

Damian Garde Regeneron has advanced dupilumab, regarded by many as the company's next big innovation, into a Phase III asthma study, rolling toward an FDA submission behind its ...

Glaxo, Theravance Asthma Drug Elvar Ellipta OK’d in Japan

barbara.lempert ELVAR™ ELLIPTA™ Gains Approval in Japan for the Treatment of Asthma LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA–(Marketwired – Sep 20, ...

Rigel shares slide after another drug flops in PhII asthma study

John Carroll Shares of Rigel Pharmaceuticals took a dive this morning, dropping 17% after the South San Francisco-based biotech announced that it is burying a program for allergic asthma ...

Array BioPharma scores midstage success for asthma drug

Ryan McBride Array BioPharma has another asset on deck for a potential partnership. The Boulder, CO-based drug developer has touted upbeat Phase II data for an experimental drug in ...

Novartis says asthma blockbuster Xolair also effective against serious hives

Eric Palmer Novartis says its asthma drug Xolair can help those who suffer from chronic spontaneous urticaria, a particularly nasty form of hives. If approved, it would add some sales ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS